Batsheva Kerem

ReCode Therapeutics Presents Preclinical Data Using SORT-LNP™ and RNA Platforms to Rescue CFTR Function at the 44th European Cystic Fibrosis Conference (ECFS)

Friday, June 11, 2021 - 1:00pm

These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis.

Key Points: 
  • These data showcase the potential of our differentiated RNA-based molecular therapies to treat cystic fibrosis.
  • By leveraging our LNP platform to deliver genomic medicines, we have demonstrated the ability to restore cystic fibrosis transmembrane conductance regulator (CFTR) function through both tRNA and mRNA approaches, said David Lockhart, Ph.D., CEO & President, ReCode Therapeutics.
  • RCT223 was shown to restore CFTR function for at least 72 hours in patient-derived hBE cells after a single administration.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.

SpliSense Secures $28.5 Million in Series B Financing

Thursday, May 13, 2021 - 12:30pm

b'JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense , a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, today announced that it has closed a $28.5 million Series B funding round.

Key Points: 
  • b'JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense , a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, today announced that it has closed a $28.5 million Series B funding round.
  • SpliSense utilizes short, precisely targeted proprietary RNA stretches called ASOs to correct various mutations in the CFTR mRNA.
  • Nissim Darvish, MD, Chairman of the Board, SpliSense, "SpliSense couples Prof. Kerem\'s pioneering research on the genetic underpinnings of CF together with a strong track record in developing ASO therapies and inhaled treatments.
  • SpliSense\' pipeline includes innovative therapies in various development stages, from discovery to IND enabling studies.